Cyxone

21/12/2021

Read about Cyxone's recent CRO agreement in this article published by BioStock. CEO Tara Heitner answers questions about this important next step for Rabeximod, the treatment for rheumatoid arthritis.

https://cyxone.com/en/biostock-article-cyxones-cro-agreement-signal-phase-iib-ra-trial-is-moving-forward-as-planned/



In the preparation for the coming phase IIb trial with Rabeximod in rheumatoid arthritis, biotech company Cyxone has entered an Early Operations Agreement with an internationally renowned clinical contract research organisation. BioStock contacted CEO Tara Heitner to learn more.

29/11/2021

See CEO Tara Heitner's presentation from the Aktieportföljen event which was held on November 24th. To stay updated on Cyxone's journey in creating treatments for rheumatoid arthritis, multiple sclerosis and virally induced acute respiratory disorders such as Covid 19, follow us here and visit us at www.cyxone.com



https://www.youtube.com/watch?v=Jp8CZbVyHX8

Hör Tara Heitner (CEO) presentera Cyxone hos Aktieportföljen Live den 24e november 2021.BolagsbeskrivningCyxone AB (publ) develops disease modifying therapie...

19/11/2021

On November 24, CEO Tara Heitner will present Cyxone at Aktieportföljen Live, the Nordics biggest online event for investors. As one of 22 featured innovative companies, you can even ask questions during the streaming. We look forward to seeing you there!

https://www.borskollen.se/nyheter/27/aktieportfoljen-live-valkommen-till-nordens-storsta-digitala-investerartraff-1636978615

Varmt välkommen till Nordens största digitala investerarträff, Aktieportföljen Live, den 23-24 november! Under dagarna kommer du att digitalt kunna "träffa" hela 22 expansiva, aktuella och innovativa bolag.

17/11/2021

ICYMI - Cyxone CEO Tara Heitner's presentation at Redeye Life Science day from November 11th. Here Tara brings us up to date on Cyxone's progress in the journey to creating treatments for rheumatoid arthritis, multiple sclerosis and virally induced acute respiratory disorders such as Covid 19.

Discover a vast selection of companies with in depth analysis provided by a team of experts.

09/11/2021

Cyxone’s research partner, the Medical University of Vienna, recently presented pre-clinical data supporting T20K as a treatment for multiple sclerosis in combination with a kappa opioid receptor agonist, the combination having potential expanded therapeutic utility. For more details about this exciting result, read the interview with Cyxone COO Carl-Magnus Högerkorp here - https://cyxone.com/en/biostock-article-pre-clinical-data-indicates-wider-use-for-cyxones-t20k-in-ms/

01/11/2021

Cyxone is happy to welcome Anne Louise Kirkegaard as Vice President Regulatory Affairs. She will fulfill an important role in guiding Cyxone through the regulatory processes on all programs with an immediate focus on the rheumatoid arthritis trial to ensure top-quality trial design and ex*****on in full alignment with good regulatory practice. Anne Louise is a seasoned regulatory professional with experience from Orphazyme as well as other biotechs and pharma companies.

For more information about our treatments, visit us at www.cyxone.com

30/10/2021

Want to catch up on what Cyxone has been up to in Q3, 2021? Take a look at our third quarter report where CEO Tara Heitner summarizes our work on our various treatments. Company financials are also provided.

https://cyxone.com/en/investor-relations/financial-reports/post/?id=CDD6E25AB6C04F2A

29/10/2021

Exciting news regarding the promising preclinical experiments for our T20K combination therapy for multiple sclerosis. Read the full press release here - https://cyxone.com/en/media-center/press-releases/post/?id=D67E86AA3988EC87

20/10/2021

ICYMI - In case you missed it. Here's the link to Cyxone CEO, Tara Heitner's presentation at the Aktiesparana's "Women's Evening" on October 19 - https://youtu.be/RWo6OBGdPFI

Please visit us at www.cyxone.com to find out more about our progress on treatments for rheumatoid arthritis, multiple sclerosis and virally induced acute respiratory disorders such as Covid 19.

Träffa Cyxone på BIOEurope 25-28 oktober 2021 – ett digitalt evenemang för globala partneringmöten inom life science.

19/10/2021

Today!

CEO Tara Heitner will present the latest progress in Cyxone's development of new treatments for rheumatoid arthritis, multiple sclerosis and virally induced acute respiratory disorders such as Covid-19. Tara will present in English. By clicking on the link below, you can follow the presentation and ask questions via the chat or by sending your questions before the event:
https://lnkd.in/dFpnszV

Första gången du loggar in: Välj att antingen logga in med din e-post och använd ditt medlemsnummer som lösenord eller Beställ nytt lösenord för att logga in på webbplatsen.

15/10/2021

In case you missed our CEO, Tara Heitner present at Vator Securities Healthcare Innovation Summit on October 7th, you can listen to her updating our progress on our journey of developing groundbreaking treatments for rheumatoid arthritis, multiple sclerosis and virally induced acute respiratory disorders such as Covid 19. We’re happy to present you with the link to her presentation - https://youtu.be/-iOy-VulHmw

Cyxone CEO Tara Heitner presents the company at Vator Securities Healthcare Innovation Summit. The Healthcare Innovation Summit was digital investor event wh...

11/10/2021

Cyxone CEO Tara Heitner will present at 14:00 at Aktiespararna's event highlighting the amazing women in biotech. The event will be held in Malmö on October 19th. To register or for more information, click here - https://www.aktiespararna.se/aktiviteter/kvinnokvallen-malmo-19-oktober (web page in Swedish, Tara will present in English)

Aktiespararna Event inbjuder dig som kvinnlig investerare, analytiker och journalist att ta del av Kvinnokvällen i Malmö den 19 oktober 2021. Evenemanget är en unik chans för dig att träffa de medverkande bolagen och ställa dina frågo